公开(公告)号：US20230414596A1

公开(公告)日：2023-12-28

申请号：US18253221

申请日：2021-11-19

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/451 ,  A61K31/4418 ,  A61K31/4545 ,  A61P25/00

CPC classification number: A61K31/451 ,  A61K31/4418 ,  A61K31/4545 ,  A61P25/00

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds or pharmaceutical acceptable salt thereof disclosed herein, so as to thereby treat the subject.

公开(公告)号：US20230355595A1

公开(公告)日：2023-11-09

申请号：US18324980

申请日：2023-05-28

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/44 ,  A61P25/14 ,  A61K9/48

CPC classification number: A61K31/44 ,  A61P25/14 ,  A61K9/48

Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230330073A1

公开(公告)日：2023-10-19

申请号：US18306257

申请日：2023-04-25

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/44 ,  A61P25/14 ,  A61K9/48

CPC classification number: A61K31/44 ,  A61P25/14 ,  A61K9/48

Abstract: This invention provides a method of maintaining, improving or lessening the decline of functional capacity or motor function in a human patient in a human patient with Huntington disease (HD) comprising orally administering to the patient a pharmaceutical composition comprising pridopidine.

公开(公告)号：US20230181548A1

公开(公告)日：2023-06-15

申请号：US18164587

申请日：2023-02-05

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Michael HAYDEN ,  Michal GEVA

IPC: A61K31/44 ,  A61P25/14 ,  A61K9/48

CPC classification number: A61K31/44 ,  A61P25/14 ,  A61K9/48

Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.

公开(公告)号：US20220062255A1

公开(公告)日：2022-03-03

申请号：US17513239

申请日：2021-10-28

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Hermann Kurt Russ ,  Ralph Laufer ,  Aric Orbach

IPC: A61K31/451 ,  A61P27/06 ,  A61K9/00

Abstract: This application provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject, pharmaceutical composition and uses and applications thereof.

公开(公告)号：US11207308B2

公开(公告)日：2021-12-28

申请号：US16203182

申请日：2018-11-28

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Ross Nicholas Waters ,  Eva Susanna Holm Waters

IPC: A61K31/445 ,  A61K31/4375 ,  A61K31/451 ,  A61K31/4745

Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in articular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.

公开(公告)号：US20210220342A1

公开(公告)日：2021-07-22

申请号：US17182605

申请日：2021-02-23

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael HAYDEN ,  Michal GEVA ,  Ana Cristina CARVALHO REGO

IPC: A61K31/44 ,  A61P25/28

Abstract: The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210052560A1

公开(公告)日：2021-02-25

申请号：US17019346

申请日：2020-09-13

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael Hayden ,  Michal Geva

IPC: A61K31/44 ,  A61K9/48 ,  A61P25/14

Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.

公开(公告)号：US20200179355A1

公开(公告)日：2020-06-11

申请号：US16789564

申请日：2020-02-13

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Ralph LAUFER ,  Michael HAYDEN ,  Neta ZACH

IPC: A61K31/44 ,  A61K9/00 ,  A61K31/426 ,  A61K31/4152 ,  A61K31/49 ,  A61K31/222 ,  A61K31/185 ,  A61K31/4748 ,  A61P25/14

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

公开(公告)号：US20200000785A1

公开(公告)日：2020-01-02

申请号：US16203182

申请日：2018-11-28

Applicant: Prilenia Neurotherapeutics Ltd.

Inventor： Ross Nicholas Waters ,  Eva Susanna Holm Waters

IPC: A61K31/445 ,  A61K31/4375 ,  A61K31/451 ,  A61K31/4745

Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.